BridgeBio Oncology Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 2.7 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 216.47M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical...